ONCAlert | Upfront Therapy for mRCC
Publications  >  Special Reports  >  2014  >  NSCLC (Issue 2)  >  

PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer

Naiyer A. Rizvi,MD
Published Online: Feb 26,2014
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Read more about frontline treatment considerations for lung cancer > >


Clinical Articles

PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.